ProfileGDS5678 / 1431655_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 82% 80% 81% 86% 83% 82% 82% 82% 82% 81% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9522682
GSM967853U87-EV human glioblastoma xenograft - Control 25.9453382
GSM967854U87-EV human glioblastoma xenograft - Control 35.9481482
GSM967855U87-EV human glioblastoma xenograft - Control 45.8331580
GSM967856U87-EV human glioblastoma xenograft - Control 55.8948181
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2272386
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9419983
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9298782
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9308982
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9459882
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9315382
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9205481
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0777483
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0188783